547 related articles for article (PubMed ID: 31745548)
1. Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease.
Caron NS; Southwell AL; Brouwers CC; Cengio LD; Xie Y; Black HF; Anderson LM; Ko S; Zhu X; van Deventer SJ; Evers MM; Konstantinova P; Hayden MR
Nucleic Acids Res; 2020 Jan; 48(1):36-54. PubMed ID: 31745548
[TBL] [Abstract][Full Text] [Related]
2. AAV5-miHTT-mediated huntingtin lowering improves brain health in a Huntington's disease mouse model.
Thomson SB; Stam A; Brouwers C; Fodale V; Bresciani A; Vermeulen M; Mostafavi S; Petkau TL; Hill A; Yung A; Russell-Schulz B; Kozlowski P; MacKay A; Ma D; Beg MF; Evers MM; Vallès A; Leavitt BR
Brain; 2023 Jun; 146(6):2298-2315. PubMed ID: 36508327
[TBL] [Abstract][Full Text] [Related]
3. AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington's Disease Minipig Model.
Evers MM; Miniarikova J; Juhas S; Vallès A; Bohuslavova B; Juhasova J; Skalnikova HK; Vodicka P; Valekova I; Brouwers C; Blits B; Lubelski J; Kovarova H; Ellederova Z; van Deventer SJ; Petry H; Motlik J; Konstantinova P
Mol Ther; 2018 Sep; 26(9):2163-2177. PubMed ID: 30007561
[TBL] [Abstract][Full Text] [Related]
4. Cellular Analysis of Silencing the Huntington's Disease Gene Using AAV9 Mediated Delivery of Artificial Micro RNA into the Striatum of Q140/Q140 Mice.
Keeler AM; Sapp E; Chase K; Sottosanti E; Danielson E; Pfister E; Stoica L; DiFiglia M; Aronin N; Sena-Esteves M
J Huntingtons Dis; 2016 Oct; 5(3):239-248. PubMed ID: 27689620
[TBL] [Abstract][Full Text] [Related]
5. AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington's disease.
Miniarikova J; Zimmer V; Martier R; Brouwers CC; Pythoud C; Richetin K; Rey M; Lubelski J; Evers MM; van Deventer SJ; Petry H; Déglon N; Konstantinova P
Gene Ther; 2017 Oct; 24(10):630-639. PubMed ID: 28771234
[TBL] [Abstract][Full Text] [Related]
6. AAV5-miHTT Gene Therapy Demonstrates Sustained Huntingtin Lowering and Functional Improvement in Huntington Disease Mouse Models.
Spronck EA; Brouwers CC; Vallès A; de Haan M; Petry H; van Deventer SJ; Konstantinova P; Evers MM
Mol Ther Methods Clin Dev; 2019 Jun; 13():334-343. PubMed ID: 30984798
[TBL] [Abstract][Full Text] [Related]
7. Astrocyte transduction is required for rescue of behavioral phenotypes in the YAC128 mouse model with AAV-RNAi mediated HTT lowering therapeutics.
Stanek LM; Bu J; Shihabuddin LS
Neurobiol Dis; 2019 Sep; 129():29-37. PubMed ID: 31042572
[TBL] [Abstract][Full Text] [Related]
8. Artificial miRNAs Reduce Human Mutant Huntingtin Throughout the Striatum in a Transgenic Sheep Model of Huntington's Disease.
Pfister EL; DiNardo N; Mondo E; Borel F; Conroy F; Fraser C; Gernoux G; Han X; Hu D; Johnson E; Kennington L; Liu P; Reid SJ; Sapp E; Vodicka P; Kuchel T; Morton AJ; Howland D; Moser R; Sena-Esteves M; Gao G; Mueller C; DiFiglia M; Aronin N
Hum Gene Ther; 2018 Jun; 29(6):663-673. PubMed ID: 29207890
[TBL] [Abstract][Full Text] [Related]
9. Mutant Huntingtin Is Cleared from the Brain via Active Mechanisms in Huntington Disease.
Caron NS; Banos R; Yanick C; Aly AE; Byrne LM; Smith ED; Xie Y; Smith SEP; Potluri N; Findlay Black H; Casal L; Ko S; Cheung D; Kim H; Seong IS; Wild EJ; Song JJ; Hayden MR; Southwell AL
J Neurosci; 2021 Jan; 41(4):780-796. PubMed ID: 33310753
[TBL] [Abstract][Full Text] [Related]
10. Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic.
Miniarikova J; Evers MM; Konstantinova P
Mol Ther; 2018 Apr; 26(4):947-962. PubMed ID: 29503201
[TBL] [Abstract][Full Text] [Related]
11. Functional Intercellular Transmission of miHTT via Extracellular Vesicles: An In Vitro Proof-of-Mechanism Study.
Morais RDVS; Sogorb-González M; Bar C; Timmer NC; Van der Bent ML; Wartel M; Vallès A
Cells; 2022 Sep; 11(17):. PubMed ID: 36078156
[TBL] [Abstract][Full Text] [Related]
12. A novel humanized mouse model of Huntington disease for preclinical development of therapeutics targeting mutant huntingtin alleles.
Southwell AL; Skotte NH; Villanueva EB; Østergaard ME; Gu X; Kordasiewicz HB; Kay C; Cheung D; Xie Y; Waltl S; Dal Cengio L; Findlay-Black H; Doty CN; Petoukhov E; Iworima D; Slama R; Ooi J; Pouladi MA; Yang XW; Swayze EE; Seth PP; Hayden MR
Hum Mol Genet; 2017 Mar; 26(6):1115-1132. PubMed ID: 28104789
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid mutant huntingtin is a biomarker for huntingtin lowering in the striatum of Huntington disease mice.
Caron NS; Banos R; Aly AE; Xie Y; Ko S; Potluri N; Anderson C; Black HF; Anderson LM; Gordon B; Southwell AL; Hayden MR
Neurobiol Dis; 2022 May; 166():105652. PubMed ID: 35143966
[TBL] [Abstract][Full Text] [Related]
14. Does the Mutant CAG Expansion in Huntingtin mRNA Interfere with Exonucleolytic Cleavage of its First Exon?
Liu W; Pfister EL; Kennington LA; Chase KO; Mueller C; DiFiglia M; Aronin N
J Huntingtons Dis; 2016; 5(1):33-8. PubMed ID: 27003665
[TBL] [Abstract][Full Text] [Related]
15. Loss of huntingtin function slows synaptic vesicle endocytosis in striatal neurons from the htt
McAdam RL; Morton A; Gordon SL; Alterman JF; Khvorova A; Cousin MA; Smillie KJ
Neurobiol Dis; 2020 Feb; 134():104637. PubMed ID: 31614197
[TBL] [Abstract][Full Text] [Related]
16. An RNA-targeting CRISPR-Cas13d system alleviates disease-related phenotypes in Huntington's disease models.
Morelli KH; Wu Q; Gosztyla ML; Liu H; Yao M; Zhang C; Chen J; Marina RJ; Lee K; Jones KL; Huang MY; Li A; Smith-Geater C; Thompson LM; Duan W; Yeo GW
Nat Neurosci; 2023 Jan; 26(1):27-38. PubMed ID: 36510111
[TBL] [Abstract][Full Text] [Related]
17. Huntingtin-Lowering Therapies for Huntington Disease: A Review of the Evidence of Potential Benefits and Risks.
Leavitt BR; Kordasiewicz HB; Schobel SA
JAMA Neurol; 2020 Jun; 77(6):764-772. PubMed ID: 32202594
[TBL] [Abstract][Full Text] [Related]
18. Nemo-like kinase reduces mutant huntingtin levels and mitigates Huntington's disease.
Jiang M; Zhang X; Liu H; LeBron J; Alexandris A; Peng Q; Gu H; Yang F; Li Y; Wang R; Hou Z; Arbez N; Ren Q; Dong JL; Whela E; Wang R; Ratovitski T; Troncoso JC; Mori S; Ross CA; Lim J; Duan W
Hum Mol Genet; 2020 May; 29(8):1340-1352. PubMed ID: 32242231
[TBL] [Abstract][Full Text] [Related]
19. Intrastriatal Administration of AAV5-miHTT in Non-Human Primates and Rats Is Well Tolerated and Results in miHTT Transgene Expression in Key Areas of Huntington Disease Pathology.
Spronck EA; Vallès A; Lampen MH; Montenegro-Miranda PS; Keskin S; Heijink L; Evers MM; Petry H; Deventer SJV; Konstantinova P; Haan M
Brain Sci; 2021 Jan; 11(2):. PubMed ID: 33498212
[TBL] [Abstract][Full Text] [Related]
20. Systemic delivery of mutant huntingtin lowering antisense oligonucleotides to the brain using apolipoprotein A-I nanodisks for Huntington disease.
Caron NS; Aly AE; Findlay Black H; Martin DDO; Schmidt ME; Ko S; Anderson C; Harvey EM; Casal LL; Anderson LM; Rahavi SMR; Reid GSD; Oda MN; Stanimirovic D; Abulrob A; McBride JL; Leavitt BR; Hayden MR
J Control Release; 2024 Mar; 367():27-44. PubMed ID: 38215984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
